Search | Clinical Trials Finder

Conditions: CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions: Gamunex-C, Xembify; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 6 more

Conditions: Post-polio Syndrome
Interventions: Flebogamma® 5% DIF, Placebo; Biological · Drug
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 4
States / cities: St Louis, Missouri • Syracuse, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions: IVIG, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 2,416 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1988 – 1991
U.S. locations: 8
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more

Conditions: Multiple System Atrophy
Interventions: intravenous immunoglobulin (IVIg); Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more

Conditions: Healthy Volunteers
Interventions: hepatitis B vaccine; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Altamonte Springs, Florida • Frederick, Maryland

Conditions: Kawasaki Disease
Interventions: Infliximab, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 4 Weeks to 17 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: La Jolla, California • Columbus, Ohio

Conditions: Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months; Drug
Lead sponsor: Camille N. Kotton, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Primary Immunodeficiency
Interventions: Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, Efficacy of Gammagard subcutaneously at Week 36, Efficacy of Gammagard subdermally at Week 36, Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 36, Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subdermally at Week 36; Drug
Lead sponsor: ASIS Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Westminster, California

Conditions: Spinocerebellar Ataxia
Interventions: IVIG; Biological
Lead sponsor: University of South Florida; Other
Eligibility: 10 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
Interventions: IV normal saline, IV immunoglobulin; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Failure
Interventions: IVIg and rituximab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dry Eye Disease
Interventions: GRF312 5%, Placebo Comparator; Drug · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Glendale, California • Grove, California • Newport Beach, California + 7 more

Conditions: HIV Infections
Interventions: Globulin, Immune, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 12 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 48
States / cities: Downey, California • Long Beach, California • Los Angeles, California + 29 more

Conditions: Healthy Volunteers
Interventions: TAK-881, SC Investigational Needle Sets; Biological · Device
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions: Civacir® 10%; Biological
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 15 more

Conditions: Alzheimer's Disease
Interventions: Albumin 5%, Albumin 20%, Immunoglobulin; Biological
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 22
States / cities: Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more

Conditions: CVI - Common Variable Immunodeficiency
Interventions: C1-esterase inhibitor [recombinant] (C1-INH-R); Biological
Lead sponsor: IMMUNOe Research Centers; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Centennial, Colorado

Conditions: Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
Interventions: Rituximab, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells; Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Kawasaki Disease
Interventions: Infliximab (Remicade), Intravenous immunoglobulin (IVIG); Drug · Biological
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: San Diego, California

Conditions: Immunologic Deficiency Syndromes
Interventions: GC5107; Biological
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 10
States / cities: Centennial, Colorado • North Palm Beach, Florida • Plymouth, Minnesota + 6 more

Conditions: Dry Eye
Interventions: Intravenous Immune Globulin (IVIG), Placebo; Drug
Lead sponsor: Sandeep Jain, MD; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Intravenous Immunoglobulin (IVIg) Therapy in a Home Infusion Setting
Interventions: Not listed
Lead sponsor: BriovaRx Infusion Services; Industry
Eligibility: 7 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Dermatomyositis, Inclusion Body Myositis, Polymyositis
Interventions: Gamma Globulin; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome

Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection

Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins

Phase 3 IGIV, 10% in Alzheimer´s Disease

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

ASIS for GAMMAGARD in Primary Immunodeficiency

Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia

Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

Autologous Transplant To End NMO Spectrum Disorder

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

IVIG-eye Drops Treatment for Dry Eye Disease

Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data (GOOD-SHEPARD)

Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies